The Netherlands and Luxembourg to also benefit from EU-US mutual recognition agreement for inspections

The mutual recognition agreement between the European Union (EU) and the United States (US) to recognise inspections of manufacturing sites for human medicines conducted in their respective territories has made further progress. The US Food and Drug Administration (FDA) confirmed on 10 June 2019 the capability of two additional EU Member States (The Netherlands and Luxembourg) to carry out good manufacturing practice (GMP) inspections at a level equivalent to the US. There are now a total of 26 Member States whose inspection results the FDA can rely on to replace their own inspections.